Biotech hopeful Iovance $IOVA promised a blockbuster launch of its cancer drug Amtagvi—forecasting nearly half a billion in revenue. But when reality hit, it came crashing down. In this episode of Bulls & Betrayal, we uncover how lofty projections, slow treatment rollout, and alleged internal knowledge of infrastructure issues led to a brutal 45% stock plunge. Ideal for investors, healthcare analysts, and corporate truth-seekers. Expect biotech drama, class action insights, and sharp market analysis.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Learn more or join the case at ZLK.com